Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.


TSX:MSCL - Post by User

Comment by GoldenHawkon Jun 27, 2018 4:41pm
151 Views
Post# 28240141

RE:Bold prediction

RE:Bold predictionI like your optimism but I think you are selling yourself short ( hopefully not shares ;) 

Way too much going on here! I see it doing better than .225 and even better leading up to the long weekend! Again, results are on the way and are expected to be bigger and better than the last two 
releases. Funding coming in and no pp needed. It’s a winner now and a green unicorn in time!

DrHoliday wrote: I`ll stick my neck out here, and predict that ICO will trade on heavy volume again tomorrow with another green candle and close at .225. 

At .225 cents, this is still a modest valuation of $19 million CDN, especially with Oral B Amphotericin on it`s way to corner the market and save millions of people from disease and suffering.

A $100 million market cap would yield a price of $1.20 CDN based on the current 84 mil outstanding. In a billion dollar market for this drug, it is entirely reasonable to think this possible.

DOC.


<< Previous
Bullboard Posts
Next >>